RESUMEN
BACKGROUND: Myopathy in patients being treated with corticosteroids is known primarily among chronically treated patients or in critically ill and mechanically ventilated patients receiving corticosteroids, often in high doses. AIM: To highlight the entity of acute, early onset corticosteroid-treatment-associated myopathy and its characteristics. DESIGN AND METHODS: Reporting our experience with four patients and reviewing all published reports of myopathy developing ≤14 days of initiating corticosteroid-treatment. RESULTS: Acute corticosteroid myopathy (ASM) exists, though the syndrome appears to be rare. It is characterized by unpredictability and heterogeneity, sometimes developing within 1-3 days, after a single dose, which may not be high and administered by varied routes. Proximal limb muscle weakness is the most common form, but distal limb, bulbar and respiratory muscles may be involved. Steroid cessation often leads to improvement/resolution, but irreversibility may occur. CONCLUSIONS: A high index of suspicion for the possibility of ASM is necessary to ensure drug discontinuation and recovery. This is particularly true since the entity is not widely recognized and its symptoms are often erroneously interpreted as due to the patient's underlying disease.
Asunto(s)
Glucocorticoides/efectos adversos , Enfermedades Musculares/inducido químicamente , Enfermedad Aguda , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Debilidad Muscular/inducido químicamente , Debilidad Muscular/diagnóstico , Enfermedades Musculares/diagnósticoRESUMEN
Chronic lymphocytic leukemia (CLL) is a malignant disease of small mature lymphocytes. Signals from the CLL microenvironment promote progression of the disease and induce drug resistance. This phenomenon is largely dependent on direct contact between the malignant B cells and stromal cells. CD84 belongs to the signaling lymphocyte activation molecule family of immunoreceptors, which self-associates, forming an orthogonal homophilic dimer. We therefore hypothesized that CD84 may bridge between CLL cells and their microenvironment, promoting cell survival. Our in vitro results show that CD84 expressed on CLL cells interact with CD84 expressed on cells in their microenvironment, inducing cell survival in both sides. Blocking CD84 in vitro and in vivo disrupt the interaction of CLL cells with their microenvironment, resulting in induced cell death. Thus, our findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/metabolismo , Leucemia Linfocítica Crónica de Células B/patología , Familia de Moléculas Señalizadoras de la Activación Linfocitaria/biosíntesis , Animales , Línea Celular Tumoral , Femenino , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microambiente TumoralRESUMEN
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5+ B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. Here, we show that the expression of CD84 is significantly elevated from the early stages of the disease, and is regulated by macrophage migration inhibitory factor and its receptor, CD74. Activation of cell surface CD84 initiates a signaling cascade that enhances CLL cell survival. Both downmodulation of CD84 expression and its immune-mediated blockade induce cell death in vitro and in vivo. In addition, analysis of samples derived from an on-going clinical trial, in which human subjects were treated with humanized anti-CD74 (milatuzumab), shows a decrease in CD84 messenger RNA and protein levels in milatuzumab-treated cells. This downregulation was correlated with reduction of Bcl-2 and Mcl-1 expression. Thus, our data show that overexpression of CD84 in CLL is an important survival mechanism that appears to be an early event in the pathogenesis of the disease. These findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.
Asunto(s)
Antígenos CD/fisiología , Supervivencia Celular , Leucemia Linfocítica Crónica de Células B/inmunología , Antígenos de Diferenciación de Linfocitos B/inmunología , Apoptosis , Secuencia de Bases , Estudios de Casos y Controles , Línea Celular Tumoral , Cartilla de ADN , Antígenos de Histocompatibilidad Clase II/inmunología , Humanos , Leucemia Linfocítica Crónica de Células B/patología , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Familia de Moléculas Señalizadoras de la Activación LinfocitariaRESUMEN
Direct antiglobulin test (DAT) with only complement detected on red blood cells is a rare laboratory finding, and its significance in the setting of warm autoimmune hemolytic anemia (AIHA) is controversial. During 2 years (2003-2004) 277 patients with positive DAT were recorded in the blood bank registries, 17 of them had DAT reactive with C3 alone with no cold agglutinin or other nonimmune causes for hemolysis diagnosed. Red cell eluate disclosed small amounts of IgG in two patients. In nine patients no signs of clinical hemolysis were found, however, all these patients had underlying conditions that are known to be associated with red cells autoantibodies (autoimmune disorder or malignancy). Eight patients developed AIHA, seven of them with severe hemolysis. Three patients had idiopathic AIHA, and the others have been diagnosed with infectious, lymphoproliferative and autoimmune disorders. In two patients with acute infection the hemolytic process spontaneously resolved, three responded to corticosteroid therapy, while three patients were refractory to two lines of drug therapy and underwent splenectomy. Reticulocytopenia was found in four patients. Our results emphasize that AIHA with DAT reactive with complement alone is a rare disorder and might be accompanied by severe, refractory to conventional treatment and life-threatening hemolysis.
Asunto(s)
Anemia Hemolítica Autoinmune/diagnóstico , Anticuerpos Antiidiotipos/inmunología , Ensayo de Actividad Hemolítica de Complemento , Proteínas del Sistema Complemento/inmunología , Eritrocitos/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Anemia Hemolítica Autoinmune/inmunología , Anticuerpos Antiidiotipos/sangre , Proteínas del Sistema Complemento/metabolismo , Femenino , Hemólisis/inmunología , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Cromosomas Humanos Par 12/ultraestructura , Cromosomas Humanos Par 8/ultraestructura , Células Madre Hematopoyéticas/patología , Leucemia Mielomonocítica Aguda/genética , Leucemia-Linfoma Linfoblástico de Células T Precursoras/genética , Mielofibrosis Primaria/genética , Translocación Genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Progresión de la Enfermedad , Resultado Fatal , Trasplante de Células Madre Hematopoyéticas , Humanos , Leucemia Mielomonocítica Aguda/tratamiento farmacológico , Leucemia Mielomonocítica Aguda/cirugía , Masculino , Persona de Mediana Edad , Leucemia-Linfoma Linfoblástico de Células T Precursoras/tratamiento farmacológico , SíndromeRESUMEN
Increased risk of haematological malignancies has been described in Gaucher disease patients; however, high-grade lymphoma has been rarely observed. We report two patients with Gaucher disease and sicca syndrome diagnosed with aggressive lymphoma involving the parotid gland. A 29-year-old woman with Gaucher disease developed tumour of the left parotid gland. She reported chronic arthralgias, xerostomia and xerophthalmia. Parotid gland biopsy disclosed diffuse large B-cell lymphoma. No lymphadenopathy was found. Bone biopsy revealed focal lymphomatous infiltration consistent with stage IV disease. MACOP-B chemotherapy regimen (cyclophosphamide, adriamycin, methotrexate, bleomycin, vincristine, prednisone) resulted in complete remission for 15 years. A 76-year-old patient with Gaucher disease suffered from dry-mouth feeling. He developed a left parotid gland tumour. CT scan disclosed diffuse lymphadenopathy, pleural effusion and multiple lung nodules. A cervical lymph node biopsy revealed mantle cell lymphoma. Fine-needle aspiration of the parotid gland showed lymphoma cells. Immunochemotherapy with fludarabine, cyclophosphamide and rituximab resulted in complete remission. Accumulation of the glucocerebroside in Gaucher disease activates macrophages, inducing release of pro-inflammatory cytokines which may be involved in the pathogenesis of second malignancy. Patients with Gaucher disease bear an increased risk of haematological malignancies; however, aggressive lymphoma has been described only occasionally. In both our patients the presenting sign of lymphoma was tumour of the parotid gland. The patients suffered from sicca syndrome, which increases risk for developing lymphoma. The underlying Gaucher disease and sicca syndrome might be implicated as immunological triggers for lymphoma occurrence and its propensity for the parotid gland in these patients.
Asunto(s)
Enfermedad de Gaucher/complicaciones , Linfoma no Hodgkin/diagnóstico , Neoplasias de la Parótida/diagnóstico , Síndrome de Sjögren/complicaciones , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica , Femenino , Enfermedad de Gaucher/patología , Humanos , Linfoma de Células B/diagnóstico , Linfoma de Células B/etiología , Linfoma de Células B Grandes Difuso/diagnóstico , Linfoma de Células B Grandes Difuso/etiología , Linfoma de Células del Manto/diagnóstico , Linfoma de Células del Manto/etiología , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/etiología , Linfoma no Hodgkin/patología , Masculino , Estadificación de Neoplasias , Neoplasias de la Parótida/tratamiento farmacológico , Neoplasias de la Parótida/etiología , Neoplasias de la Parótida/patología , Síndrome de Sjögren/patología , Resultado del TratamientoAsunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Busulfano/uso terapéutico , Trombocitemia Esencial/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/efectos adversos , Busulfano/administración & dosificación , Busulfano/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del TratamientoRESUMEN
The incidence of non-Hodgkin's lymphoma (NHL) in individuals infected with human immunodeficiency virus (HIV) is more than 60 times higher than in matched controls. In the vast majority of cases aggressive pathological subtypes and advanced stages prevail, extranodal sites are involved and systemic symptoms are present. The prognosis of HIV-NHL remains poor and the optimal therapeutic approach has yet to be defined. We report a 48-year-old Ethiopian woman with advanced-stage HIV infection, who developed diffuse large cell, immunoblastic type B-cell NHL and was treated with a modified CHOP-like chemotherapy combined with Rituximab and supported with growth factor. Highly active antiretroviral therapy (HAART) and opportunistic infections prophylaxis were administered concomitantly. The patient completed 6 cycles of therapy and currently, 76 weeks after diagnosis, is in complete clinical remission. Despite the fact that there was a transient decrease in the CD4-positive cell number and a 1.5 log increase in plasma viral load there were no opportunistic infections, nor was life-threatening toxicity seen. Rituximab seems a well-tolerable and advantageous adjunct to chemotherapy and HAART in the treatment of aggressive HIV-associated NHL andshould be investigated in large trials in the future.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Linfoma Relacionado con SIDA/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales de Origen Murino , Terapia Antirretroviral Altamente Activa , Femenino , Humanos , Linfoma Relacionado con SIDA/patología , Linfoma de Células B Grandes Difuso/patología , Linfoma de Células B Grandes Difuso/virología , Infecciones Oportunistas/prevención & control , Inducción de Remisión , Rituximab , Carga ViralRESUMEN
Several cytokines have been found to play a role in the pathogenesis of B-CLL. In the present study using reverse-transcriptase polymerase chain reaction (RT-PCR), FACS analysis and immunofluorescence we have shown the constitutive expression of IL-11 and IL-11R alpha in B-chronic lymphocytic leukemia (B-CLL). The expression level of IL-11R alpha in B-CLL cells is much higher than in PBL of normal donors. Recombinant human IL-11 (rhIL-11) activates B-CLL cells, leading to morphologic alterations of the cells and increase in cell number and size. Short-term cultivation in the presence of rhIL-11 did not lead to quantitative changes in the ratio of the living vs apoptotic and dead cells. However, in contrast to rhIL-6, pretreatment with rhIL-11, did not cause B-CLL cells to be resistant to the action of dexamethasone. These data suggest an essential role for the IL-11/IL11 R alpha system in the pathogenesis of the malignant B-CLL cells.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/sangre , Receptores de Interleucina/genética , Anciano , Anciano de 80 o más Años , Apoptosis/efectos de los fármacos , Linfocitos B/efectos de los fármacos , Linfocitos B/metabolismo , Linfocitos B/patología , Estudios de Casos y Controles , Técnicas de Cultivo de Célula , Humanos , Interleucina-11/genética , Interleucina-11/farmacología , Subunidad alfa del Receptor de Interleucina-11 , Leucemia Linfocítica Crónica de Células B/etiología , Activación de Linfocitos/efectos de los fármacos , Persona de Mediana Edad , ARN Mensajero/análisis , ARN Mensajero/metabolismo , Receptores de Interleucina-11 , Proteínas Recombinantes/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa InversaAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunización Pasiva , Inmunoterapia , Linfoma de Células B/terapia , Linfoma no Hodgkin/terapia , Púrpura Trombocitopénica Idiopática/etiología , Neoplasias de las Glándulas Suprarrenales , Adulto , Alquilantes/uso terapéutico , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20/inmunología , Terapia Combinada , Resistencia a Medicamentos , Humanos , Inmunoglobulina G/sangre , Inmunosupresores/uso terapéutico , Linfoma de Células B/sangre , Linfoma de Células B/complicaciones , Linfoma de Células B/inmunología , Linfoma no Hodgkin/sangre , Linfoma no Hodgkin/complicaciones , Linfoma no Hodgkin/inmunología , Masculino , Proteínas de Neoplasias/sangre , Neoplasias Primarias Múltiples , Feocromocitoma , Púrpura/etiología , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , Púrpura Trombocitopénica Idiopática/cirugía , Inducción de Remisión , Rituximab , EsplenectomíaRESUMEN
Primary effusion lymphoma (PEL) is a recently described rare type of non-Hodgkin's lymphoma occurring almost exclusively in HIV infected people. Human herpesvirus 8 (HHV-8), has been linked with PEL, and a causative relationship has been suggested. In the vast majority of PEL cases Epstein-Barr virus (EBV) has been found in the tumour cells. We describe here an elderly human immune deficiency (HIV) seronegative man with intractable chest pain and pleural effusion. The diagnosis of malignant lymphoma was suggested cytologically and confirmed histologically following pleural biopsy. No lymphadenopathy or organ involvement with lymphoma was found. Systemic chemotherapy with a modified CHOP regimen with G-CSF support gradually led to the resolution of the chest pain and ultimately resulted in a complete clinical remission (CCR). The presence of HHV-8 was demonstrated by PCR using paraffin-embedded tissue samples from the involved pleura, whereas EBV-associated genetic material was absent. The patient remained in CCR for 18 months and died of an unrelated cause (cerebrovascular event). Only 11 other cases with clinical and virological features similar to those of our patient have been reported in the literature. Analysis of these rare cases suggests HIV-negative EBV-negative PEL to be a distinct clinical entity with epidemiological features resembling classical KS and supports an EBV-independent role for HHV-8 in the pathogenesis of PEL.
Asunto(s)
Linfoma no Hodgkin/etiología , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Dolor en el Pecho , Ciclofosfamida/administración & dosificación , ADN Viral/sangre , Doxorrubicina/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Seronegatividad para VIH , Herpesvirus Humano 8/genética , Humanos , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/virología , Masculino , Derrame Pleural Maligno/tratamiento farmacológico , Derrame Pleural Maligno/etiología , Derrame Pleural Maligno/virología , Prednisona/administración & dosificación , Inducción de Remisión , Vincristina/administración & dosificaciónRESUMEN
We describe a 33 y/o HIV(+) woman who developed advanced Hodgkin's disease (HD) during the 2nd trimester of her pregnancy. Combination chemotherapy and antiretroviral treatment along with opportunistic infection prophylaxis were administered. At term, while in partial remission, she delivered by a Caesarian section a healthy baby, PCR-negative for HIV. A complete remission was later achieved upon completion of the chemotherapy regimen. Since both the incidence of HD and the proportion of young women among the HIV(+) individuals are increasing, it seems important to recognize that successful completion of pregnancy with no deterioration of accepted surrogate parameters of HIV disease progression is achievable in a carefully treated HIV(+) pregnant woman with advanced HD.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Seropositividad para VIH/complicaciones , Enfermedad de Hodgkin/complicaciones , Complicaciones Infecciosas del Embarazo , Complicaciones Neoplásicas del Embarazo , Adulto , Quimioterapia Combinada , Femenino , Seropositividad para VIH/tratamiento farmacológico , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Lamivudine/uso terapéutico , Masculino , Embarazo , Resultado del Embarazo , Inducción de Remisión , Estavudina/uso terapéutico , Zidovudina/uso terapéuticoRESUMEN
B-chronic lymphocytic leukemia (B-CLL) is characterized by the clonal accumulation of CD5+ B cells. It has been suggested that CLL cells may be regulated by inhibitory and growth-promoting signals exerted by autologous T cells. We have recently described a model for human B-CLL in which peripheral blood mononuclear cells (PBMCs) are transplanted into the peritoneal cavity of lethally irradiated mice radioprotected with bone marrow from mice with severe combined immunodeficiency. In this model, adoptive transfer of low-stage PBMCs leads to marked engraftment of T cells or combined T and CLL cell engraftment, whereas infusion of high-stage PBMCs leads to dominance of CLL cells with a miniscule level of T-cell engraftment. This mutual exclusive pattern of engraftment indicated that T cells might control the expansion of tumor cells in the peritoneum of recipient BALB/c mice. In the present study, we further investigated this question and we demonstrate that in vivo T-cell depletion, using OKT3 antibody, markedly enhances the engraftment of B-CLL cells from patients with early-stage disease. In mice receiving PBMCs from 11 donors with advanced-stage disease, the results were more heterogeneous. In five patients the results were similar to those observed in early stage, whereas in two cases no CLL cell engraftment was found in the absence of T cells. The addition of purified T cells to PBMCs led to a substantial decrease of CLL engraftment in three advanced-stage cases. These results strengthen the working hypothesis that autologous T cells can actively suppress the expansion of the pathological cells in human-->mouse radiation chimera. This effect is prominent in early-stage disease, whereas in advanced stage suppressive and/or stimulatory effects may occur in different patients. The interaction of T cells with tumor cells and the potential of autologous T cell/immune-therapy in CLL can be further explored in this model.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/inmunología , Transfusión de Linfocitos , Quimera por Radiación/inmunología , Linfocitos T/inmunología , Anciano , Anciano de 80 o más Años , Animales , Progresión de la Enfermedad , Femenino , Humanos , Depleción Linfocítica , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos NOD , Ratones Desnudos , Ratones SCID , Persona de Mediana Edad , Muromonab-CD3/farmacología , Estadificación de Neoplasias , Formación de Roseta , Trasplante HeterólogoRESUMEN
We report a retrospective survey of 35 patients (18 males and 17 females) with B-Prolymphocytic leukemia (B-PLL) followed for a median of 63 months. Twelve patients fulfilled Galton's original clinical and hematological criteria, presented with prominent splenomegaly and hyperleukocytosis and showed rapid progression soon after diagnosis. Twelve cases with gradually increasing spleen size and prolymphocyte count had an indolent course. Seven of this group are alive 68 to 164 months after diagnosis, whereas five died from causes unrelated to PLL. Eleven patients who never developed impressive leukocytosis had a variable prognosis. In the group of 17 patients treated with chlorambucil and prednisone (CP) or cyclophosphamide, vincristine, prednisone (COP) 8 achieved a partial remission (PR) with a median response of 32 months. In the group of six cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) treated patients one achieved a complete remission and two PR (median response was maintained for 30 months). Three patients treated with 2CdA achieved good PR. Six patients remained untreated. Median survival was 65 months and the probability of overall survival for 3, 5, and 10 years was 63%, 56% and 35%, respectively. Anemia < 11 g/dl and lymphocytosis > 100 x 10(9)/l were predictors of shorter survival in this group of patients. Age over 70, gender, B-symptoms at presentation, spleen size, thrombocytopenia, low IgG and complement levels, presence of paraproteinemia and the pattern of bone marrow infiltrate were not significant. Our findings show that all B-PLL may not have such a poor prognosis as described in earlier reports. The existence of prior symptoms evolving gradually after years to obvious PLL and cases with mild prolymphocytosis could possibly lead to underdiagnosis of the entity. Identification and follow-up of such cases may suggest a different natural history, variable prognostic features and different survival curves for B-PLL patients. In the light of the above, we suggest that the therapeutic approach for B-PLL should always relate to the severity of the disease.
Asunto(s)
Leucemia de Células B/diagnóstico , Leucemia Prolinfocítica/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Cladribina/uso terapéutico , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Inmunofenotipificación , Leucemia de Células B/inmunología , Leucemia de Células B/mortalidad , Leucemia de Células B/terapia , Leucemia Prolinfocítica/inmunología , Leucemia Prolinfocítica/mortalidad , Leucemia Prolinfocítica/terapia , Linfocitosis/diagnóstico , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Esplenomegalia/diagnóstico , Tasa de SupervivenciaAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ciclosporina/uso terapéutico , Eritropoyetina/uso terapéutico , Inmunosupresores/uso terapéutico , Leucemia Linfocítica Crónica de Células B/terapia , Aplasia Pura de Células Rojas/terapia , Vidarabina/análogos & derivados , Antígenos CD/sangre , Antineoplásicos/uso terapéutico , Relación CD4-CD8 , Hemoglobinas/análisis , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunofenotipificación , Leucemia Linfocítica Crónica de Células B/sangre , Leucemia Linfocítica Crónica de Células B/complicaciones , Leucemia Linfocítica Crónica de Células B/inmunología , Persona de Mediana Edad , Prednisona/administración & dosificación , Aplasia Pura de Células Rojas/sangre , Aplasia Pura de Células Rojas/complicaciones , Aplasia Pura de Células Rojas/inmunología , Vidarabina/uso terapéuticoAsunto(s)
Ascitis/patología , Crisis Blástica/patología , Leucemia Linfocítica Crónica de Células B/patología , Leucemia Prolinfocítica/patología , Derrame Pleural Maligno/patología , Anciano , Anciano de 80 o más Años , Ascitis/etiología , Progresión de la Enfermedad , Femenino , Humanos , Leucemia Prolinfocítica/complicaciones , Células Madre Neoplásicas/patología , Derrame Pleural Maligno/etiología , Esplenomegalia/etiología , Esplenomegalia/patologíaRESUMEN
Chronic lymphocytic leukemia (CLL) represents 30% of all leukemias in Caucasians. In East Europe and USA the disease incidence is high while in Asia and Africa CLL is rare. The present study deals with 302 cases of B cell CLL and related disorders; 207 patients originating from Europe and America (Ashkenazi Jews) and 95 descendants from Asia, The Mediterranean or Africa (Sephardic Jews). The patients were recruited during 1975-1996 in a single center covering the Hashfela region -- a Southern area of Israel with a current population of 430000 inhabitants. Incidence of the disease, clinical pattern, biological parameters, prognosis and outcome were investigated and compared in both ethnic groups. The results of this study show a high incidence of CLL in Israel. The mean annual age-adjusted incidence 4.3 per 100000 person-year is among the highest reported values. Our study confirms previous data on the prevalence of CLL in Ashkenazi compared to Sephardic Jews. The rise in CLL rate in the reviewed period occurred in both populations, mainly in the Sephardic group. The relative risk for Ashkenazies compared to Sephardics decreased from 6.0 in the 1975-1979 period to 2.4 in 1990-1996. A high rate of CLL was found in new immigrants from the former USSR with 26 cases de novo diagnosed and 11 prevalent cases not included in this series among approximately 60000 new immigrants in the ara over the last 8 years. No differences were found in clinical, laboratory and immunological parameters at the time of diagnosis in the two ethnic groups. The follow-up showed a similar pattern in the disease evolution. A preliminary study of immunoglobulin heavy chain rearrangement performed in 14 patients showed no significant differences in JH hybridization in the early stages of the disease, but more aberrations in advanced CLL in the Ashkenazi group. Our findings suggest that ethnic origin of the patients itself does not affect the biological and clinical behavior of this disease.